新辅助化疗对宫颈癌预后影响的荟萃分析

Meta-analysis about Effect of Neoadjuvant Chemotherapy on Cervical Cancer

目的探讨新辅助化疗对宫颈癌预后的影响。方法检索国内外已发表的相关文献,选择比较新辅助化疗加放疗或手术和单独手术或放疗对宫颈癌患者预后影响的所有随机对照试验,提取资料后对5年生存率进行荟萃分析,计算新辅助化疗组相对于对照组死亡危险的优势比(OR)评价新辅助化疗对患者预后的影响。结果从1992～2007年,有15项研究入选,共2881例患者,新辅助治疗组1450例,对照组1431例,分析结果显示新辅助治疗组与对照组比较,合并OR值为0.70,95%可信区间为[0.60,0.82],P<0.00001。结论新辅助化疗适用于宫颈癌的治疗,可改善预后。

Objective To detect the effect of neoadjuvant chemotherapy on the prognosis of patients with cervical cancer by Mate-analysis. Methods Based on the related data published domestic and abroad, all the random check test about the effect of neoadjuvant chemotherapy binded with radiotherapy or operation and single operation or radiotherapy on the prognosis of cervical cancer were included and compared, the 5- year survival rate of every methods were analyzed by recta-analysis, potence ratio about death risk of neoadju- vant chemotherapy group compared with control group was calculated to evaluate the effect of this method on the prognosis of patients. Results 15 trials from 1992 to 2007 was included into Meta-analysis. Which in- cludes 2881 patients, 1450 cases in neoadjuvant chemotherapy group, 1431 cases in the control group, the an- alyzed results showed that there is a significant difference in survival between neoadjuvant chemotherapy group and control group. The pooled OR was 0.70, with a 95% confidence interval （0.60,0.82）, P 〈 0. 00001. Conclusion The neoadjuvant chemotherapy is feasible to the therapy for cervical cancer, which can promote the prognosis.